Your browser doesn't support javascript.
loading
In patients with controlled acromegaly, indices of glucose homeostasis correlate with IGF-1 levels rather than with type of treatment.
Decock, Amelie; Verroken, Charlotte; Van de Velde, Frederique; Vilsbøll, Tina; Holst, Jens Juul; T'Sjoen, Guy; Lapauw, Bruno.
Afiliação
  • Decock A; Department of Endocrinology, Ghent University Hospital, Ghent, Belgium.
  • Verroken C; Department of Endocrinology, Ghent University Hospital, Ghent, Belgium.
  • Van de Velde F; Department of Endocrinology, Ghent University Hospital, Ghent, Belgium.
  • Vilsbøll T; NNF Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
  • Holst JJ; Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
  • T'Sjoen G; NNF Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
  • Lapauw B; Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
Clin Endocrinol (Oxf) ; 95(1): 65-73, 2021 07.
Article em En | MEDLINE | ID: mdl-33715210
OBJECTIVE: Acromegaly is accompanied by abnormalities in glucose and lipid metabolism which improve upon treatment. Few studies have investigated whether these improvements differ between treatment modalities. This study aimed to compare glucose homeostasis, lipid profiles and postprandial gut hormone response in patients with controlled acromegaly according to actual treatment. DESIGN: Cross-sectional study at a tertiary care centre. PATIENTS: Twenty-one patients with acromegaly under stable control (ie insulin growth factor 1 [IGF1] levels below sex- and age-specific thresholds and a random growth hormone level <1.0 µg/L) after surgery (n = 5), during treatment with long-acting somatostatin analogues (n = 10) or long-acting somatostatin analogues + pegvisomant (n = 6) were included. MEASUREMENTS: Glucose, insulin, total cholesterol and high-density lipoprotein-cholesterol were measured in fasting serum samples. Glucose, insulin, triglycerides, glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 were measured during a mixed meal test. Insulin sensitivity was evaluated by a hyperinsulinaemic-euglycaemic clamp. RESULTS: There were no significant differences in glucose tolerance, insulin sensitivity or postprandial gut hormone responses between the three groups. Positive correlations between IGF1 levels and HbA1c, fasting glucose and insulin levels and postprandial area under the curve (AUC) of glucose and insulin and also an inverse association between IGF1 and glucose disposal rate were found in the whole cohort (all p < .05, lowest p = .001 for postprandial AUC glucose with rs  = 0.660). CONCLUSION: In this cross-sectional study in patients with controlled acromegaly, there were no differences in glucose homeostasis or postprandial substrate metabolism according to treatment modality. However, a lower IGF1 level seems associated with a better metabolic profile.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Acromegalia / Hormônio do Crescimento Humano Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Clin Endocrinol (Oxf) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Bélgica

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Acromegalia / Hormônio do Crescimento Humano Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Clin Endocrinol (Oxf) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Bélgica